Literature DB >> 9346487

Knockout-transgenic mouse model of sickle cell disease.

T M Ryan1, D J Ciavatta, T M Townes.   

Abstract

When transgenic mice that expressed human sickle hemoglobin were mated with mice having knockout mutations of the mouse alpha- and beta-globin genes, animals were produced that synthesized only human hemoglobin in adult red blood cells. Similar to many human patients with sickle cell disease, the mice developed a severe hemolytic anemia and extensive organ pathology. Numerous sickled erythrocytes were observed in peripheral blood. Although chronically anemic, most animals survived for 2 to 9 months and were fertile. Drug and genetic therapies can now be tested in this mouse model of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346487     DOI: 10.1126/science.278.5339.873

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  110 in total

Review 1.  Gene therapy for the hemoglobin disorders: past, present, and future.

Authors:  D A Persons; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Reaping of nitric oxide by sickle cell disease.

Authors:  Jack R Lancaster
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Induction of human fetal globin gene expression by a novel erythroid factor, NF-E4.

Authors:  W Zhou; D R Clouston; X Wang; L Cerruti; J M Cunningham; S M Jane
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors:  Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

Review 5.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

6.  Correction of sickle cell disease by homologous recombination in embryonic stem cells.

Authors:  Li-Chen Wu; Chiao-Wang Sun; Thomas M Ryan; Kevin M Pawlik; Jinxiang Ren; Tim M Townes
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

7.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

8.  Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway.

Authors:  Gael F P Bories; Scott Yeudall; Vlad Serbulea; Todd E Fox; Brant E Isakson; Norbert Leitinger
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

9.  Impaired Collateral Vessel Formation in Sickle Cell Disease.

Authors:  Derick Okwan-Duodu; Laura Hansen; Giji Joseph; Alicia N Lyle; Daiana Weiss; David R Archer; W Robert Taylor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-15       Impact factor: 8.311

10.  A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease.

Authors:  Zhenning He; J Eric Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.